Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00857766 · ClinicalTrials.gov registry record · Phase 4

A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

A Phase 4 study of Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 4
Development phase
249
Enrollment target
20
Study locations

NCT00857766 is a Phase 4 study of Pulmonary Disease, Chronic Obstructive that has completed, run by GlaxoSmithKline. The registered enrollment target is 249 participants, below the 1,041-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (76% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00857766, a Phase 4 study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 4
Development phase
249 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate in patients with Chronic Obstructive Pulmonary Disease (COPD) if Advair DISKUS™ 250/50mcg BID modifies arterial stiffness which is a measure associated with risk of heart disease.

Conditions Studied

Pulmonary Disease, Chronic Obstructive

Interventions

  • OTHER Placebo
  • DRUG ADVAIR DISKUS™ 250/50mcg

Study Locations (20)

South Carolina

  • GSK Investigational Site - Charleston
  • GSK Investigational Site - Gaffney
  • GSK Investigational Site - Greenville
  • GSK Investigational Site - Spartanburg

Alabama

  • GSK Investigational Site - Birmingham
  • GSK Investigational Site - Jasper
  • GSK Investigational Site - Mobile

Missouri

  • GSK Investigational Site - Chesterfield
  • GSK Investigational Site - Saint Charles
  • GSK Investigational Site - St Louis

California

  • GSK Investigational Site - San Diego
  • GSK Investigational Site - Torrance

Pennsylvania

  • GSK Investigational Site - Downington
  • GSK Investigational Site - Pittsburgh

Arizona

  • GSK Investigational Site - Phoenix

Connecticut

  • GSK Investigational Site - Hartford

Idaho

  • GSK Investigational Site - Coeur d'Alene

Trial Details

FieldValue
Enrollment Target 249 participants
Start Date 2009-03
Est. Completion 2010-03
Phase Phase 4

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00857766

The ClinicalTrials.gov registry entry for NCT00857766 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 249 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,041-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (76% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00857766 reports 20 study locations spanning 11 distinct geographic areas - top geographies include South Carolina, Alabama, Missouri.

Frequently Asked Questions

What is clinical trial NCT00857766 about?

NCT00857766 is a clinical study titled "A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)". The purpose of this study is to evaluate in patients with Chronic Obstructive Pulmonary Disease (COPD) if Advair DISKUS™ 250/50mcg BID modifies arterial stiffness which is a measure associated with risk of heart disease.

What is the current status of trial NCT00857766?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 249 participants. The study started on 2009-03. Estimated completion is 2010-03.

What conditions does trial NCT00857766 study?

This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.

What interventions are being tested in trial NCT00857766?

The interventions under investigation include: Placebo (OTHER), ADVAIR DISKUS™ 250/50mcg (DRUG).

Who is sponsoring clinical trial NCT00857766?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00857766 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pulmonary Disease, Chronic Obstructive

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pulmonary Disease, Chronic Obstructive

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.